Pre-operative Evaluation of Kidney & Pancreas Transplant Patients
This trial is active, not recruiting.
|Conditions||kidney transplantation, pancreas transplantation|
|Treatment||dobutamine stress echocardiogram|
|Sponsor||University of Nebraska|
|Start date||April 2003|
|End date||March 2012|
|Trial size||150 participants|
|Trial identifier||NCT00580437, 142-03-FB|
Examine the clinical utility of the dobutamine stress contrast echoes and angiograms obtained routinely in the evaluation of patients prior to kidney or pancreas transplantation.
|Intervention model||single group assignment|
Provide a higher sensitivity required to adequately assess risks in the pancreas/ kidney transplant evaluation
time frame: I year
Eliminate the need for costly and invasive additional procedures
time frame: 1 year
Male or female participants at least 19 years old.
Inclusion Criteria: - Patients who are being evaluated for a kidney and or pancreas transplant and scheduled for a dobutamine stress echocardiogram and a coronary angiogram will be eligible to participate Exclusion Criteria: - Patients with unstable angina at the time of their evaluation, or who have a severe underlying cardiomyopathy or valve disease will be excluded.
|Official title||The Analysis of Data Collected During Angiography and Dobutamine Stress Contrast Echocardiograms in the Pre-Evaluation of Kidney and Pancreas Transplant Patients|
|Principal investigator||Thomas R Porter, MD|
|Description||Although there is an increasing quantity of data demonstrating the value of stress echo in risk stratifying patients for cardiac risk prior to major non-cardiac surgery, the current clinical practice utilized for assessing patients being evaluated for kidney or pancreas transplantation is both a stress echocardiogram and a coronary angiogram. This gap in opinion appears to be a concern on the part of both nephrologists, endocrinologists, and surgeons that the stress echocardiogram may miss significant angiographic disease that could result in major post-operative complications in this high-risk subgroup of patients (unstable angina, non-fatal infarction, or death).|
Call for more information